Axsome Therapeutics (AXSM) received from FDA proposed labeling for AXS-05 product candidate with respect to its NDA for AXS-05 for treatment of major depressive disorder

Axsome Therapeutics (NASDAQ: AXSM) disclosed:

On June 24, 2022, Axsome Therapeutics, Inc. (the “Company”) received from the U.S. Food and Drug Administration (the “FDA”) proposed labeling for the Company’s AXS-05 product candidate with respect to its New Drug Application (the “NDA”) for AXS-05 for the treatment of major depressive disorder. The Company is reviewing the proposed labeling and will reply to the FDA to secure final labeling agreement.

You May Also Be Interested In

• WeTrade Group (WETG) Partners with Jiqing Bio Company to Exclusively Sell Monkeypox Test Kits and Antigen Tests
• PDS Biotechnology (PDSB) Announces Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
• FDA Approves Enhertu for HER2-Low Breast Cancer